TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:IMR) ) has shared an update.
Imricor Medical Systems, Inc. has submitted its Vision-MR Diagnostic Catheter for FDA 510(k) approval, marking a significant step towards expanding its MRI-compatible electrophysiology devices in the U.S. market. This move, along with the recent submission of the NorthStar 3D mapping system, aims to establish a comprehensive, radiation-free platform for cardiac procedures, potentially transforming the industry and enhancing Imricor’s market position.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
More about Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
Imricor Medical Systems, Inc. is a pioneer in developing MRI-compatible products for cardiac catheter ablation procedures, aiming to improve the safety and effectiveness of interventional medical procedures by utilizing real-time MRI guidance instead of x-ray fluoroscopy. The company offers products such as the Vision-MR Ablation Catheter, which is approved in the EU, KSA, and New Zealand for treating type 1 atrial flutter, and is seeking regulatory approvals in the U.S. and other markets.
Average Trading Volume: 338,868
Technical Sentiment Signal: Buy
See more insights into IMR stock on TipRanks’ Stock Analysis page.